Abstract: The present invention relates to computer-based clinical decision support tools including, computer-implemented methods, computer systems, and computer program products for clinical decision support. These tools assist the clinician in identifying epilepsy patients who are candidates for surgery and utilize a combination of natural language processing, corpus linguistics, and machine learning techniques.

Abstract: The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.

Abstract: Embodiments provide a deep learning framework to accurately segment liver and spleen using a convolutional neural network with both short and long residual connections to extract their radiomic and deep features from multiparametric MRI. Embodiments will provide an “ensemble” deep learning model to quantify biopsy derived liver fibrosis stage and percentage using the integration of multiparametric MRI radiomic and deep features, MRE data, as well as routinely available clinical data. Embodiments will provide a deep learning model to quantify MRE-derived liver stiffness using multiparametric MRI, radiomic and deep features and routinely-available clinical data.

Abstract: The present disclosure provides methods method for alleviating liver injury using a Farnesoid X receptor (FXR) activator.

Abstract: A specialized computing environment that includes hardware and data security features to enable competitive organizations to co-analyze proprietary data without revealing the underlying proprietary data to unauthorized users. Proprietary data are stored in volatile memory, which may be automatically erased according to pre-stored criteria. The analysis is performed automatically by a processing unit without human intervention. Analytical results are sanitized (e.g., using data masking) to prevent the analytical result from being tracible to any particular data source. Sanitized analytical results are output without outputting the underlying proprietary data (except to users authorized to validate analytical results). The computing environment is enclosed within a secure enclosure (e.g.

Abstract: Embodiments provided herein relate to methods and compositions for treating mesothelioma and/or a small cell lung cancer that express midkine.

Abstract: The disclosure is directed to precision dosing regimens to achieve a target concentration of alemtuzumab in a subject of between about 0.15 ?g/mL-about 0.6 ?g/mL at day 0, or the day of a transplantation event involving allogeneic hematopoietic cells. The disclosure is also directed to methods of increasing the percentage of a patient population having a concentration of alemtuzumab of between about 0.15 ?g/mL-about 0.6 ?g/mL at day 0.

Abstract: The disclosure provides methods of modulating an immune response by inhibiting BFL1, and related methods for treating and preventing diseases and disorders characterized by inflammation, especially neutrophil induced inflammation.

Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of a squamous epithelium in a target tissue using alpha-1 proteinase inhibitors to replenish SPINK7 protein and/or SPINK7 anti-proteinase activity in the target tissue, and related methods and compositions.

Abstract: The disclosure relates to methods for pain management in the perioperative context, particularly through the use of the DNA methylation status of the human OPRM1 gene as a biomarker for increased susceptibility to perioperative pain, and related methods and compositions.

Abstract: Some embodiments of the invention include inventive compounds (e.g., compounds of Formula (I) or (Ia)). Other embodiments include compositions (e.g., pharmaceutical compositions) comprising the inventive compound. Still other embodiments of the invention include compositions (e.g., pharmaceutical compositions) for treating, for example, certain diseases or nerve injury using the inventive compounds. Some embodiments include methods of using the inventive compound (e.g., in compositions or in pharmaceutical compositions) for administering and treating (e.g., for treating disease, such as multiple sclerosis (MS), or for treating nerve damage). Further embodiments include methods for making the inventive compounds. Additional embodiments of the invention are also discussed herein.

Abstract: A method of inhibiting inflammation with milk oligosaccharides or glycoconjugates containing the oligosaccharides.

Abstract: One or more techniques and/or systems are disclosed for a gastrostomy tube having a proximal portion and a distal portion with at least one lumen extending therethrough. The proximal portion includes first, second, and third ports that are each operably coupled to the proximal portion with the first port configured to provide for suction of contents from a patient's stomach, and the third port configured to provide fluid to an inflatable balloon. The distal portion includes a plurality of first openings configured to transport contents to and from the patient's stomach, at least one second opening configured to cooperate with the second port to provide sump-type function, and a curved portion having a gradual bend of approximately 45°-135°. The curved portion directs a distal end of the tube radially outward and away from a longitudinal axis of the tube.

Abstract: A method for spatial resolution enhanced imaging is provided. The method includes determining a target region of a subject being imaged; estimating an achievable spatial resolution; selecting an increased spatial resolution that is greater than a predetermined spatial resolution and equal to or less than the achievable spatial resolution; and acquiring image data of the target region with the increased spatial resolution. A method for enhancing the contrast between the region of interest and other tissue region in the image data acquired with the increased spatial resolution and other tissue region in image data acquired with the predetermined spatial resolution due to the intrinsic partial volume effect is also provided.

Abstract: Methods and compositions disclosed herein generally relate to methods of improving clinical and economic outcomes to address adverse effects related to anesthesia, analgesics, opioids, and inadequate pain relief. Embodiments of the invention relate to the association between genes, specific polymorphisms of genes, and non-genetic factors with inadequate pain relief and anesthesia-, analgesic, and/or opioid-related adverse effects. Embodiments of the invention can be used to determine and manage patient risk factors for development of adverse perioperative effects and can allow for personalized anesthesia and pain management for improvement of pain control and reduction of anesthesia-, analgesic-, and opioid-related adverse outcomes. These methods and compositions apply to non-surgical pain management with opioids.

Abstract: Disclosed are methods for making a vascularized hollow organ derived from human intestinal organoid (HIOs). The HIOs may be obtained from human embryonic stem cells (ESC's) and/or induced pluripotent stem cells (iPSCs), such that the HIO forms mature intestinal tissue. Also disclosed are methods for making a human intestinal tissue containing a functional enteric nervous system (ENS).

Abstract: A gastrojejunostomy tube may comprise a jejunal tube, gastric tube, and a balloon tube. The jejunal tube may comprise a port at a proximal end and an opening at a distal end. The gastric tube may comprise a port at a proximal end and an opening at a distal end. The gastric tube may be operably, fixedly coupled with the jejunal tube to form a tubular portion of the gastrojejunostomy tube. The balloon tube may comprise a port at a proximal end and a balloon at a distal end, and may be sized to dispose the balloon in the stomach of the target patient. The balloon tube may be selectably removable from the tubular portion of the gastrojejunostomy tube such that the tubular portion remains in the target patient and the balloon tube is removed from the target patient and replaced by another balloon tube.

Abstract: A small molecule compound IODVA1 has been found to have cellular inhibitory activity against several transformed cell lines including Ras-driven cells. IODVA1 decreases cell-cell and cell-extra cellular matrix interactions and reduces growth of Ras-driven tumors. Applicants also synthesized compound NIRA2 and showed in vitro and in vivo efficacy and potency against models of Ph+(BCR-ABL1) B-ALL and of colon adenocarcinoma xenografts.

Abstract: The invention provides methods of treating an allergic inflammatory condition characterized by inflammation of the squamous epithelium of a target tissue by administering to the subject a pharmaceutical composition comprising a kallikrein 5 (KLK5) inhibitor, and a pharmaceutically acceptable carrier.

Abstract: Disclosed are methods for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof. Further disclosed are compositions for use in the disclosed methods, used for treating a myelodyspastic syndrome (MDS) and/or an acute myeloid leukemia (AML) in an individual in need thereof.